This book explains in detail the diagnosis, management, and treatment of comorbid disorders in patients with autism spectrum disorders (ASD). Important insights are provided into the nature of the symptoms of psychiatric comorbidities in these patients, and particularly children and adolescents, with a view to assisting clinicians in reaching a correct diagnosis that will permit the implementation of appropriate treatment strategies, whether psychological or pharmacological. The full range of potential comorbidities is considered, including mood disorders, anxiety disorders, obsessive-compulsive disorder, schizophrenia spectrum and other psychotic disorders, eating disorders, disruptive behavioral disorders, Tourette’s disorder, and substance-related disorders. In each case guidance is provided on how to avoid incorrectly attributing symptoms to ASD and on treatment options. Psychiatric Comorbidities in Autism Spectrum Disorders will be of value to all practitioners who are confronted by patients with these complex co-occurring conditions.
Luigi Mazzone MD Ph.D., is the author of several book chapters and numerous research papers published in leading peer-reviewed psychiatric journals. He is actually working as a Clinical Researcher at the Division of Child Psychiatry at Bambino Gesù Hospital in Vatican, Rome, Italy.Benedetto Vitiello is a psychiatrist with expertise in psychopharmacology and treatment research. He has been part of many publicly funded clinical trials testing the effects of interventions in children and adolescents, such as the Multimodal Treatment of Children with Attention Deficit Hyperactivity Disorder (MTA), the Treatment for Adolescents with Depression Study (TADS), the Research Units on Pediatric Psychopharmacology (RUPP) network studies, the Preschoolers with ADHD Treatment Study (PATS), and the Treatment of Early Onset Schizophrenia Study (TEOSS). He is adjunct Professor of Psychiatry at the Johns Hopkins University in Baltimore, Maryland. He works at the National Institutes of Health in Bethesda, Maryland, as the chief of the Treatment and Preventive Interventions Research Branch.